Search

Luminal breast cancer (BC) is associated with less immune activation, and the significance of stromal lymphocytic infiltration (sTIL) is more uncertain than in other BC subtypes. The aim of this study was to investigate the predictive and prognostic value of sTIL in early luminal BC. The study was performed with an observational design in a prospective cohort of 345 patients with predominantly high-risk luminal (hormone receptor positive, HER2 negative) BC and with luminal B features (n = 286), in which the presence of sTIL was analyzed with validated methods. Median sTIL infiltration was 5% (Q1–Q3 range (IQR), 0–10). We found that sTIL were associated with characteristics of higher biological and clinical aggressiveness (tumor and lymph node proliferation and stage, among others) and that the percentage of sTIL was predictive of pathologic complete response in patients treated with neoadjuvant chemotherapy (OR: 1.05, 95%CI 1.02–1.09, p < 0.001). The inclusion of sTIL (any level of lymphocytic infiltration: sTIL > 0%) in Cox regression multivariable prognostic models was associated with a shorter relapse-free interval (HR: 4.85, 95%CI 1.33–17.65, p = 0.016) and significantly improved its performance. The prognostic impact of sTIL was independent of other clinical and pathological variables and was mainly driven by its relevance in luminal B BC.

While the role of miR-200c in cancer progression has been established, its expression and prognostic role in breast cancer is not completely understood. The predictive role of miR-200c in response to chemotherapy has also been suggested by some studies, but only limited clinical evidence is available. The purpose of this study was to investigate miR-200c-3p in the plasma and primary tumor of BC patients. The study design included two cohorts involving women with locally advanced (LABC) and metastatic breast cancer. Tumor and plasma samples were obtained before and after treatment. We found that miR-200c-3p was significantly higher in the plasma of BC patients compared with the controls. No correlation of age with plasma miR-200c-3p was found for controls or for BC patients. MiR-200c-3p tumor expression was also associated with poor overall survival in LABC patients treated with neoadjuvant chemotherapy, independently of pathological complete response or clinical stage. Our findings suggest that plasmatic miR-200c-3p levels could be useful for BC staging, while the tumor expression of miR-200c-3p might provide further prognostic information beyond residual disease in BC treated with neoadjuvant chemotherapy.

Aim To determine predictive factors of axillary lymph node dissection (ALND) results in breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NACT), and subsequent staging using Targeted Axillary Dissection (TAD). Material and method Case-control study between January 2016 and August 2019. Patients with BC, cN1 staging, marked with a metallic clip prior to NACT, and subsequently staged with TAD and ALND were included. They were divided into 2 groups: ALND patients with or without metastatic involvement (group 1 and group 2, respectively). We carried out a univariate analysis comparing clinical, radiological, surgical and pathological variables, and a logistic regression, (dependent variable: positive result of ALND; independent variables: number of suspicious lymph nodes in diagnostic ultrasound, positive hormone receptors, HER2 positive, complete clinical-radiological response to NACT, positive TAD, and biopsy of ≤2 nodes in TAD). A score for prediction of a metastatic ALND was proposed, with an internal validation study. Results 60 patients were included: Group 1: 33 (55.0%); Group 2: 27 (45.0%). Tumor size (Odds Ratio (OR) = 1.67; 95%CI 1.02–2.74), number of suspected nodes in ultrasound (OR = 2.20; 95%CI 1.01–4, 77), HER2 positive (OR 0.04; 95%CI 0.003–0.54), clinical-radiological response to NACT (OR = 0.07; 95%CI 0.01–0.75), and positive TAD (OR 15.48; 95%CI 1.68–142.78) were independent predictors of a positive result in ALND. We developed a “positive ALND predictive score”, with good calibration (Hosmer-Lemeshow test: p = 0.65), and discrimination (AUC = 0.93; 95% CI 0, 87–0.99), with highest Youden index (0.7) at cut-off point of 17% risk of positive ALND (sensitivity = 100%; specificity = 70%). Conclusion Tumor size, number of suspected nodes, positive HER2, response to NACT, and metastatic TAD are independent predictors of ALND. The predictive score for positive ALND would be a good indicator to safely omit ALND.

Background: Endocrine resistance is a major cause of therapeutic failure in metastatic breast cancer (MBC). The information provided by DNA sequencing of plasma cell free DNA (cfDNA) and by the analysis of circulating tumor cells (CTC) may be useful to determine the occurrence and type of endocrine resistance. However, different levels of concordance between cfDNA and CTC, and also between liquid biopsy and tissue biopsy, have been reported. Thus, the best strategy for performing DNA sequencing in the setting of therapeutic decisions for luminal MBC patients is not well defined. The purpose of this study was to determine the concordance between DNA sequencing data from CTC, cfDNA, metastasis, and primary tumor in endocrine-resistant luminal MBC.Methods: Using the same panel (10 genes) we performed simultaneous sequencing of cfDNA, CTC, metastases and primary tumor in 38 patients with luminal MBC. CTC isolation was performed with an Epcam-based immunomagnetic system. Concordance of DNA sequencing data of the different types of sample was analyzed and correlated with clinical data. Results: CTC were detected in 21% of the patients. The rate of detection of genetic alterations was 87.5% for CTC, 61.5% for cfDNA, 63.2% for metastasis and 67.7% for primary tumor, and involved mainly TP53, PIK3CA, ESR1 and AKT1. A higher number of mutations was found in cfDNA of MBC patients with progressive disease (p=0.02) and the same trend was observed for endocrine resistance (p=0.08), especially for PIK3CA, ESR1 and AKT1 mutations. Global concordance was low to intermediate between CTC and cfDNA, but significantly higher between CTC and metastasis. Concordance also varied according to the specific genetic alteration, with no ESR1 mutations detected in CTC and with a low concordance for PIK3CA and AKT1 mutations between CTC and cfDNA samples.Conclusions: DNA sequencing of different types of tumor samples (cfDNA, CTC, metastasis and primary tumor) may provide different rates of genomic alterations detection in luminal endocrine-resistant MBC. A moderate to low concordance, with discordances depending both on the clinical situation and on the sequenced gene, support the complementarity of the different samples, with cfDNA and metastatic tissue as the preferred sources of tumor DNA.

Background: A prognostic model based on the results of molecular analysis of sentinel lymph nodes (SLN) is needed to replace the information that staging the entire axilla provided. The aim of the study is to conduct an external validation of a previously developed model for the prediction of 5-year DFS in a group of breast cancer patients that had undergone SLN biopsy assessed by the One Step Nucleic Acid Amplification (OSNA) method. Methods: We collected retrospective data of 889 patients with breast cancer, who had not received systemic treatment before surgery, and who underwent SLN biopsy and evaluation of all SLN by OSNA. The discrimination ability of the model was assessed by the area under the ROC curve (AUC ROC), and its calibration by comparing 5-years DFS Kaplan–Meier estimates in quartile groups of model predicted probabilities (MPP). Results: The AUC ROC ranged from 0.78 (at 2 years) to 0.73 (at 5 years) in the training set, and from 0.78 to 0.71, respectively, in the validation set. The MPP allowed to distinguish four groups of patients with heterogeneous DFS (log-rank test p < 0.0001). In the highest risk group, the HR were 6.04 [95% CI 2.70, 13.48] in the training set and 4.79 [2.310, 9.93] in the validation set. Conclusions: The model for the prediction of 5-year DFS was successfully validated using the most stringent form of validation, in centers different from those involved in the development of the model. The external validation of the model confirms its utility for the prediction of 5-year DFS and the usefulness of the TTL value as a prognostic variable., This study was supported by Sysmex España S.L.

The possibility of avoiding axillary lymphadenectomy (AL) in patients with breast cancer (BC) after positive sentinel lymph node biopsy (SLNB) and low metastatic burden (ó = 2 positive lymph nodes) has put into question the role of axillary ultrasound due to the risk of overtreatment after positive axillary lymph node biopsy with low metastatic burden. Our aim was to identify clinical and ultrasound features to detect low and high metastatic burden.A retrospective study of 405 BC patients with primary surgical treatment with axillary ultrasound examination and subsequent AL after positive fine needle aspiration (FNA) or SLNB. The low and high tumor burdens after AL were correlated with clinical and ultrasound variables: lymph node morphology (UN1 to UN5), number of suspicious lymph nodes, and Berg level.Positive FNA, lymph node morphology UN4 (focal thickening with displacement of the fatty hilum) or UN5 (complete replacement of the fatty hilum) and2 suspicious lymph nodes were significantly associated with "high metastatic burden". Lymph node morphology UN2 and UN3, even after FNA+, lymph node morphology UN4 after FNA-, and suspicious lymph nodes at Berg level I were low metastatic burden criteria. Lymph node morphology UN5, lymph node morphology UN4 after FNA+, two nodes or more with UN4/UN5 morphology, and suspicious lymph nodes at Berg levels II and III with FNA+ were associated with high metastatic burden.Axillary lymph node ultrasound data for patients with early BC allows predicting the axillary metastatic burden, guiding the optimal clinical management of the axilla.

Aim to study the feasibility and value of “Targeted Axillary Dissection” (TAD) in cN1 breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NACT), in order to avoid unnecessary axillary lymph node dissection (ALND). Materials and methods Design: Prospective observational study. Inclusion criteria: Patients with histologically confirmed cN1 staging BC and treated with NACT between January 2016 and August 2019 who accomplished clinical response. Method: Fine-Needle Aspiration (FNA) positive axillary nodes were marked with a metallic clip prior to neoadjuvant treatment. All patients were summited to TAD and ALND. Analysis of data: We performed [1]: a feasibility analysis of clinical, radiological and pathological variables, as well as difficulties and complications of the TAD [2]; a diagnostic test study of the sentinel lymph node biopsy (SLNB), clipped lymph node biopsy (BCLIP) and their combination (TAD), using ALND as the Gold Standard. Results 60 patients were included. 43 patients (71.7%) had a complete clinical lymph node response to NACT. Neither limitations nor complications in clip placement were found. Intraoperative location of the clipped node was problematic in 7 cases (11.7%). The pathological complete response rate (pCR) was 30.5% (18 patients) and ypN0 staging rate was 38.3% (23 patients). Sensitivity values of each technique were: SLNB: 80.9% (95%CI: 61.8–100); BCLIP: 80.8% (95%CI: 63.7–97.8); TAD: 92.6% (95%CI: 80.9–100) with negative predictive values of: SLNB: 84.6% (95%CI: 68.8–100); BCLIP: 81.0% (95%CI: 63.7–97.8); TAD: 91.3% (95%CI: 77.6–100). Conclusion TAD is feasible and valid to rule out axillary metastatic involvement in cN1 breast cancer patients who respond to NACT.

Resumen Introduccion Describir las principales caracteristicas clinicas, anatomopatologicas, terapeuticas y evolutivas de una serie amplia de tumores estromales gastrointestinales (GIST). Metodos Estudio observacional de una serie de 66 casos de GIST tratados en nuestro hospital de 2002 a 2015. Seleccionamos variables relacionadas con los antecedentes personales, las manifestaciones clinicas, el tratamiento medico y quirurgico, la anatomia patologica y la morbimortalidad. Anadimos una revision de la literatura para correlacionarla con nuestros resultados. Resultados La localizacion mas frecuente fue el estomago (65,2%), en el que destaco como region predominante el fondo. La manifestacion clinica mas habitual fue la hemorragia digestiva (45,5%), seguida del hallazgo casual tras la realizacion de alguna prueba de imagen o procedimiento invasivo (33,3%). Recibieron cirugia 58 pacientes (90,6%), el 15,5% de caracter urgente. El 69% de los GIST tenian un tamano entre 2 y 10 cm. La mortalidad al ano debida al tumor fue de un 7,9% (5 casos), todos ellos relacionados con extension local o a distancia, o complicacion quirurgica. Conclusiones La variabilidad clinica de los GIST es muy amplia. El tratamiento de primera eleccion es la cirugia, que es factible en la mayoria de los casos y debe ser lo mas conservadora posible. El pronostico es variable, dependiendo del tamano y del indice de proliferacion, por lo que debe realizarse un seguimiento estrecho. No existe un marcador tumoral claramente asociado a un peor pronostico, por lo que se necesitan nuevos estudios de biologia molecular con el objetivo de encontrar dianas terapeuticas.

The analysis of breast cancer residual tumors after neoadjuvant chemotherapy (nCT) may be useful for identifying new biomarkers. MicroRNAs are known to be involved in oncogenic pathways and treatment resistance of breast cancer. Our aim was to determine the role of miR-18a, a member of the miR-17-92a cluster, in breast cancer behavior and outcome after nCT. Pre- and post-nCT tumor miR-18a expression was retrospectively assessed by qRT-PCR in 121 patients treated with nCT and was correlated with survival outcomes and with clinical and pathological characteristics. Breast cancer-derived MCF-7 and MDA-MB-231 cell lines were transfected with miR-18a and anti-miR-18a to evaluate the biological effects of this molecule. In addition, whole-transcriptome expression analysis was performed. High miR-18a expression in post-nCT residual tumors was found to be associated with a significantly worse overall survival [hazard ratio (HR): 2.80, 95% confidence interval (CI): 1.01–7.76] and a strong trend towards a poorer disease-free survival (HR: 2.44, 95% CI: 0.99–5.02) compared to low miR-18a expressing post-nCT residual tumors. Clinical and experimental data were found to be in conformity with the proliferative effects of miR-18a, which showed a significant correlation with Ki67 and MYBL2 expression, both in pre- and post-nCT tumors and in public databases. In vitro analysis of the role of miR-18a in breast cancer-derived cell lines showed that a high expression of miR-18a was associated with a low expression of the estrogen receptor (ER), a decreased sensitivity to tamoxifen and an enrichment in luminal B and endocrine resistance gene expression signatures. From our data we conclude that post-nCT miR-18a expression in breast cancer serves as a negative prognostic marker, especially in luminal tumors. Clinical, in vitro and in silico data support the role of miR-18a in breast cancer cell proliferation and endocrine resistance and suggest its potential utility as a biomarker for additional adjuvant treatment in patients without a pathologic complete response to neoadjuvant therapy.

Resumen Antecedentes y objetivo El cancer tiroideo puede manifestarse clinicamente por la presencia de un nodulo cervical, o constituir un hallazgo casual en el estudio histologico de la glandula extirpada con diagnostico, a priori, benigno. El objetivo del presente estudio fue estudiar las diferencias clinicas, de manejo quirurgico y curso evolutivo entre los tumores tiroideos incidentales y los tumores detectados clinicamente. Material y metodos Estudio retrospectivo de pacientes intervenidos por enfermedad tiroidea, ya fuese benigna o maligna, en el periodo comprendido entre enero de 2000 y marzo de 2014. De 1.415 pacientes que se sometieron a algun tipo de cirugia tiroidea se identificaron un total de 264 neoplasias, de las cuales 170 fueron incidentales. Se realizo comparacion entre carcinomas incidentales versus no incidentales. Ademas, entre los incidentales se compararon los casos cuya indicacion quirurgica fue enfermedad de Graves frente a bocio multinodular. Resultados Los carcinomas incidentales presentaron estadios mas precoces y requirieron cirugia menos agresiva. No se observaron diferencias en las complicaciones quirurgicas entre ambos grupos, aunque tanto la mortalidad como las tasas de recidiva fueron notablemente mayores en el grupo de no incidentales (4,4% vs 0% y 13,2% vs 4,8% respectivamente). Los carcinomas desarrollados sobre enfermedad de Graves no mostraron diferencias respecto al resto de los tumores incidentales, respecto a complicaciones, mortalidad o recidiva tras la cirugia. Conclusiones El cancer tiroideo en estadios iniciales presenta mayor supervivencia y mejor respuesta al tratamiento quirurgico.

Background and objective Thyroid cancer may be clinically evident as a tumor mass in the neck or as a histopathological incidental finding after thyroid surgery for an apparent benign condition. Our objective was to assess the differences in clinical signs, surgical management, and course between incidental and clinically diagnosed thyroid tumors. Methods A retrospective study was conducted on patients operated on for benign or malignant thyroid disease from January 2000 to March 2014. Among the 1415 patients who underwent any thyroid surgery, 264 neoplasms were found, of which 170 were incidental. A comparison was made of incidental versus non-incidental carcinomas. Among incidental carcinomas, cases whose indication for surgery was Graves’ disease were compared to those with multinodular goiter. Results Incidental carcinomas were in earlier stages and required less aggressive surgery. There were no differences in surgical complications between incidental and clinical tumors, but mortality and relapses were markedly higher in non-incidental cancers (4.4% vs 0% and 13.2% vs 4.8% respectively). Carcinomas developing on Graves’ disease showed no differences from all other incidental tumors in terms of complications, mortality, or relapse after surgery. Conclusions Early stage thyroid cancer has better survival and prognosis after surgical treatment.

Aim. To study the feasibility and validity of ultrasound-guided pre-chemotherapy marking of metastatic axillary lymph nodes followed by targeted axillary dissection (TAD), in breast cancer patients undergoing neoadjuvant chemotherapy (NACT). Material and method Prospective diagnostic test study conducted between January 2016 and March 2018. Patients with breast cancer and indication for NACT, cN1 or cN2 axillary staging, were included. A clip was placed in the affected lymph node prior to NACT. A sentinel lymph-node biopsy (SLNB) and a clipped lymph-node biopsy (BCLIP) were conducted, followed by axillary lymph node dissection (ALND). Location rate (LR) and negative predictive value (NPV) were evaluated, taking SLNB, BCLIP and their combination (TAD) as evaluated tests and metastatic involvement in the ALND specimen as the gold standard. Results Twenty-three patients were included in the study. Sentinel lymph node could only be detected in 19 cases (LR = 80.61%), whereas BCLIP was successful in 22 (LR = 95.65%). The sentinel lymph node coincided with the marked lymph node in 14 patients (60.9%). We found a NPV for the SLNB of 0.85 (95%CI: 0.61–1.0), whereas for TAD it was 1.00 (95%CI: 0.74–1.0). Conclusion TAD is a feasible test for axillary restaging after NACT, with a higher success rate than SLNB.

Introduction This study was aimed to assess the main clinical, pathological and therapeutic characteristics of a cohort of gastrointestinal stromal tumors (GIST). Methods Observational study including 66 patients diagnosed with GIST admitted to our hospital between 2002 and 2015. Parameters related to medical history, clinical manifestations, medical and surgical treatment, histopathology, and morbi-mortality were studied. A review of the literature was included to correlate with the results. Results The most frequent location of GIST in our patients was the stomach (65.2%), in which the gastric fondo was the predominant region. The most common clinical manifestation was gastrointestinal hemorrhage (45.5%), followed by incidental finding after imaging or invasive procedures (33.3%). 58 patients underwent surgery (90.6%), 15.5% were urgent. A total of 69% of the GISTs had a size between 2 and 10 cm. The one-year mortality was 7.9%, all cases related to local or remote extension, or surgical complications. Conclusion There is a large clinical variability among GIST cases. The first choice of treatment is surgery, which is feasible in most cases and should be as conservative as possible. The prognosis varies depending on the size and proliferation index, thus close follow-up should be performed. No tumor marker is clearly associated with a poor prognosis. New molecular biology studies are needed in order to find therapeutic targets.

Background Scanning histological or cytological preparations is a crucial element in the process of digitization of Pathology Departments, along with the traceability of tissue samples and the reports management. The scanning time and the high size of the files are still considered suboptimal for full implementation. In order to optimize time and space a comparative study of the workflow performed by histotechnicians in our center has been carried out. Material & Methods A total of 25 endoscopic samples were selected with the intention of comparing different parameters (scanning time, error rate during scanning and hard disk storage) between the original histological glass slides (group A: 2 slides per case, 50 preparations) and new sections, with levels grouped into a single slide (group B: 1 slide per case, 25 preparations). They were scanned at 20x magnification in routine way using the Ventana iScan Coreo scanner (Roche diagnostics). The process was repeated 4 times to calculate averages. Results The average scanning time was 5 hours 40 minutes (6m 48s / slide) in group A and 5 hours 10 minutes (12m 24s / slide) in group B. The error rate was 6.1% in group A and 3,8% in group B. The space occupied on the hard disk was 11.87 GB in group A and 9.6 GB in group B (475 MB/case vs 385 MB/case, respectively). The average number of tissue sections per case was 7 in group A and 8 in group B. Conclusion There is a clear benefit of standardizing and optimizing the number of cuts per slide in terms of storage (saving 19%), biopsy sampling (14% more tissue) and error rate (37% less), including a not negligible decrease in the scanning time (9%) in the study conducted., Diagnostic Pathology, Vol 2 No 1 (2016): 2016

Introduction/ Background Scanning histological or cytological preparations is a crucial element in the process of digitization of Pathology Departments, along with the traceability of tissue samples and the reports management. The scanning time and the high size of the files are still considered suboptimal for full implementation. Aims In order to optimize time and space a comparative study in our center has been carried out. Methods A total of 25 endoscopic samples (5 esophageal, 5 gastric, 5 duodenal, 5 colonic inflammatory, and 5 colonic neoplastic) were selected with the intention of comparing different parameters (scanning time, error rate during scanning and hard disk storage) between the original histological glass slides (group A: 2 slides per case, 50 preparations) and new sections, with levels grouped into a single slide (group B: 1 slide per case, 25 preparations). They were scanned at 20x magnification in routine way using the Ventana iScan scanner Coreo (Roche diagnostics). The process was repeated 4 times to calculate averages. Results The average scanning time was 5 hours 40 minutes (6m 48s / slide) in group A and 5 hours 10 minutes (12m 24s/slide) in group B. The error rate was higher than it had been found in previous studies (2-3%) with 6% errors in group A and 3,9% errors in group B. The space occupied on the hard disk was 11.87 GB in group A and 9.6 GB in group B (475 MB/case vs 385 MB/case, respectively). The average number of tissue sections per case was 7 in group A and 8 in group B. Conclusions: There is a clear benefit of standardizing and optimizing the number of cuts per slide in terms of storage (saving 19%), biopsy sampling (14% more tissue) and error rate (35% less), including a not negligible decrease in the scanning time (9%) in the study conducted., Diagnostic Pathology, Vol 1 No 8 (2016): 13. European Congress on Digital Pathology

Background Angiogenesis is a key process for tumor progression and a target for treatment. However, the regulation of breast cancer angiogenesis and its relevance for clinical resistance to antiangiogenic drugs is still incompletely understood. Recent developments on the contribution of microRNA to tumor angiogenesis and on the oncogenic effects of miR-17-92, a miRNA cluster, point to their potential role on breast cancer angiogenesis. The aim of this work was to establish the contribution of miR-20a, a member of miR-17-92 cluster, to tumor angiogenesis in patients with invasive breast carcinoma. Methods Tube-formation in vitro assays with conditioned medium from MCF7 and MDA-MB-231 breast cancer cell lines were performed after transfection with miR-20a and anti-miR20a. For clinical validation of the experimental findings, we performed a retrospective analysis of a series of consecutive breast cancer patients (n = 108) treated with neoadjuvant chemotherapy and with a full characterization of their vessel pattern and expression of angiogenic markers in pre-treatment biopsies. Expression of members of the cluster miR-17-92 and of angiogenic markers was determined by RT-qPCR after RNA purification from FFPE samples. Results In vitro angiogenesis assays with endothelial cells and conditioned media from breast cancer cell lines showed that transfection with anti-miR20a in MDA-MB-231 significantly decreased mean mesh size and total mesh area, while transfection with miR-20a in MCF7 cells increased mean mesh size. MiR-20a angiogenic effects were abrogated by treatment with aflibercept, a VEGF trap. These results were supported by clinical data showing that mir-20a expression was higher in tumors with no estrogen receptor or with more extensive nodal involvement (cN2-3). A higher miR-20a expression was associated with higher mean vessel size (p = 0.015) and with an angiogenic pattern consisting in larger vessels, higher VEGFA expression and presence of glomeruloid microvascular proliferations (p

The effects of breast cancer conventional chemotherapy on tumor angiogenesis need to be further characterized. Neoadjuvant chemotherapy is an ideal model to evaluate the results of chemotherapy, allowing intra-patient direct comparison of antitumor and antiangiogenic effects. We sought to analyze the effect of neoadjuvant chemotherapy on tumor angiogenesis and its clinical significance in breast cancer. Breast cancer patients (n = 108) treated with neoadjuvant sequential anthracyclines and taxanes were studied. Pre- and post-chemotherapy microvessel density (MVD) and mean vessel size (MVS) were analyzed after CD34 immunohistochemistry and correlated with tumor expression of pro- and antiangiogenic factors (VEGFA, THBS1, HIF1A, CTGF, and PDGFA) by qRT-PCR. Angiogenic measures at diagnosis varied among breast cancer subtypes. Pre-treatment higher MVS was associated with triple-negative subtype and more advanced disease. Higher MVS was correlated with higher VEGFA (p = 0.003), while higher MVD was correlated with lower antiangiogenic factors expression (THBS1, p < 0.0001; CTGF, p = 0.001). Increased angiogenesis at diagnosis (high MVS and glomeruloid microvascular proliferation) and higher VEGFA expression were associated with tumor recurrence (p = 0.048 and 0.009, respectively). Chemotherapy-induced angiogenic response (defined as decreased MVD) was present in 35.2 % of patients. This response correlated with an increase in antiangiogenic factors (THBS1) without changes in VEGFA expression, and it was associated with tumor downstaging, but not with clinical response, pathologic complete response, or prognosis. Global effects of chemotherapy mainly consisted in an increased expression of antiangiogenic factors (THBS1, CTGF), with significant changes neither of tumor VEGFA nor of MVS. Conventionally scheduled neoadjuvant chemotherapy exerts antiangiogenic effects, through an increase in antiangiogenic factors, THBS1 and CTGF, but the expression of VEGFA is maintained after treatment. Better markers of angiogenic response and a better understanding of the cooperation of chemotherapy and antiangiogenic therapy in the neoadjuvant clinical scenario are needed.